StreetInsider.com News Articles

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

Fri, 27 Feb 2026 08:51:57 -0500

OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet’s position for life sciences and healthcare organizations generating real-world evidence (RWE).

This launch drives rapid expansion of subscription contracts, including multi-year deals representing millions in

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

Fri, 27 Feb 2026 08:51:57 -0500

This launch drives rapid expansion of subscription contracts, including multi-year deals representing millions in

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

Fri, 27 Feb 2026 08:50:00 -0500

MINNEAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the successful November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet’s position for life sciences and healthcare organizations generating real-world evidence (RWE).

This launch drives

OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry

Fri, 27 Feb 2026 08:50:00 -0500

This launch drives

OneMedNet partners with ViuHealth to expand autoimmune data platform

Thu, 26 Feb 2026 08:40:42 -0500

OneMedNet Corporation (NASDAQ: ONMD) announced a strategic partnership with ViuHealth to enhance its autoimmune disease dataset capabilities. The collaboration will integrate ViuHealth's longitudinal autoimmune patient data into OneMedNet's iRWD platform, which is powered by Palantir Foundry.

Under the agreement, ViuHealth will provide ongoing autoimmune disease data that captures patient journeys, treatment adherence, disease flares, and outcomes. This data will be incorporated into OneMedNet's regulatory-grade Real-World Data platform to support pharmaceutical and biotechnology companies developing therapies for autoimmune conditions.

The autoimmune therapeutics market is projected to exceed $166 billion globally in 2026, according to the companies. Autoimmune diseases affect approximately 8% of the

OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

Thu, 26 Feb 2026 08:40:00 -0500

MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic partnership with ViuHealth, a digital health company specializing in autoimmune disease populations.

This partnership expands OneMedNet’s autoimmune clinical ontology, to the OneMedNet iRWD™ platform—powered by Palantir Foundry—further increasing the scale, diversity, and longitudinal depth of its regulatory-grade Real-World Data. Under the agreement, ViuHealth will provide ongoing, longitudinal autoimmune disease data, strengthening OneMedNet’s portfolio of high-value specialty datasets and supporting research, AI model development, HEOR initiatives, and regulatory-aligned use cases.

Autoimmune Real-World Data

OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers

Thu, 26 Feb 2026 08:40:00 -0500

Autoimmune Real-World Data

OneMedNet signs data licensing deal with Risorius for EEG biomarkers

Tue, 24 Feb 2026 08:57:15 -0500

OneMedNet Corporation (NASDAQ: ONMD) entered into a data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers for central nervous system research.

Under the three-month licensing agreement, Risorius will receive access to electroencephalography and polysomnography waveform data paired with clinical context and longitudinal follow-up information. The company will use the datasets for research and development, model development, and validation efforts for its AI Co-Scientist platform designed to support neurological and psychiatric clinical studies.

The agreement includes multi-modal data featuring EEG and PSG waveforms combined with longitudinal clinical data. OneMedNet will deliver the data continuously over the project duration

OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers

Tue, 24 Feb 2026 08:53:00 -0500

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced a strategic data licensing agreement with Risorius Co., Ltd., a neurotechnology company developing EEG-based digital biomarkers and AI-powered research platforms for central nervous system (CNS) indications across neurology, psychiatry, and sleep. This new relationship supports OneMedNet’s continued focus on expanding its base of subscription contracts, adding multi-year agreements that represent millions of dollars in incremental recurring revenue.